Soluble B7-H3 in Colorectal Cancer
Authors:
- 1 November 2023
- journal article
- research article
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 176 (1) , 87-90
Abstract
We present the results of comparative ELISA of the concentration of soluble form of immunity checkpoint B7-H3 (sB7-H3) in the serum of patients with coloreKeywords
This publication has 14 references indexed in Scilit:
- B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal CancerClinical Colorectal Cancer, 2021
- B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinomaLaboratory Investigation, 2020
- Immunoregulatory protein B7‐H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cellsPigment Cell & Melanoma Research, 2017
- ILT4 drives B7‐H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7‐H3 co‐expression correlates with poor prognosis in non‐small cell lung cancerFEBS Letters, 2015
- Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29cBritish Journal of Cancer, 2014
- Characterization of a Soluble B7-H3 (sB7-H3) Spliced from the Intron and Analysis of sB7-H3 in the Sera of Patients with Hepatocellular CarcinomaPLOS ONE, 2013
- Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinomaCancer Immunology, Immunotherapy, 2010
- The contrasting role of B7-H3Proceedings of the National Academy of Sciences, 2008
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- B7-H3: A costimulatory molecule for T cell activation and IFN-γ productionNature Immunology, 2001